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http:WHAT THIS PAPER ADDS
This is the ﬁrst paper that calculates, based on data of a large cohort of arteriovenous access ﬁstulae (AVF)
operations and 10-year follow-up, the functional dialysis use of common types of AVF and comes to precise
estimates of which strategy is most effective. The maturation time of AVF without interventions was accurately
estimated. This guides planning of access and may serve as a benchmark to judge interventions to improve AVF
maturation.Objectives: The aim was to study primary failure, maturation times, and survival of common arteriovenous
ﬁstulae (AVF) to aid planning for vascular access, and to assess which strategy results in most dialysis days.
Methods: This was a longitudinal cohort study. Two databases of access operations and dialysis sessions over 9
years with 12-year follow-up were reviewed. Functional dialysis use is deﬁned as achieving six consecutive
dialysis sessions with two needles on AVF. Primary failure (PF) is failure to achieve functional dialysis use.
Maturation time, calculated only for patients on dialysis with a central line at AVF operation, is deﬁned from the
operation date to the functional dialysis date. Cumulative patency, including PF, is calculated from the operation
to date of AVF abandonment and is compared using KaplaneMeier curves and adjusted hazard ratios (HRs).
Results: A total of 1206 AVF, 689 (57%) radiocephalic AVF (RCAVF), 383 (32%) brachiocephalic AVF (BCAVF), and
134 (11%) brachiobasilic AVF (BBAVF), were analysed. PF was 23%. PF was lower for BCAVF (17%) than RCAVF
(26%) and BBAVF (26%) (p ¼ .006). PF was higher for women (OR 1.59, 95% CI: 1.21e2.09) and patients with
vascular kidney disease (OR 1.69, 95% CI: 1.19e2.59). Median maturation time was 10.3 weeks. Cumulative
patency was worse for BCAVF (HR 1.36, 95% CI: 1.03e1.81) and BBAVF (HR 1.63 95% CI: 1.12e2.38), for patients
on dialysis at AVF creation (HR 1.55, 95% CI: 1.13e2.12), and diabetics (HR 1.55, 95% CI: 1.12e1.85). RCAVFs
resulted in 3% more dialysis-person-years (py) per 100 operations for all patients and in 15% more dialysis-py in
the over 80s.
Conclusion: RCAVFs have higher PF, but better survival than other AVF, and result in more dialysis time. AVF
created pre-dialysis have better survival. An average maturation time of 10 weeks should be considered if
planning to start dialysis on an AVF.
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Guidelines on vascular access for haemodialysis agree that
arteriovenous ﬁstulae (AVF) are the preferred form of ac-
cess.1,2 AVF are associated with better patient survival than
other forms of access.3,4 The main disadvantage of AVF are
the high primary failure rates (PFs) and that they are notresponding author. Department of Vascular Surgery, Birmingham
nds Hospital, Bordesley Green East, Birmingham B9 5SS, UK.
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//dx.doi.org/10.1016/j.ejvs.2015.10.005immediately available for use. A maturation time of several
weeks is needed to ensure safe cannulation without
compromising the survival of the access.5 Observed matu-
ration times vary widely.6,7 The Dialysis Outcomes and
Practice Patterns Study (DOPPS) showed that cannulation
after surgery occurred within 8 weeks in 14% of AVF in the
United States, in 45% in the United Kingdom, and in over
90% in Europe.8 Furthermore, although there is agreement
that AVF should be placed as distally as possible, there is
discussion on which AVF is most appropriate for elderly
people, considering the high primary failure rate of radio-
cephalic ﬁstulae (RCAVF) compared with brachiocephalic
ﬁstulae (BCAVF) in this age group.9e11 Primary failure rates,
maturation times,7 and AVF survival vary with the type of
AVF and patient characteristics.12,13 Accurate contemporary
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includes PF rates, are vital for vascular access planning. This
study aims to estimate PF rates, maturation times of com-
mon AVF, and the long-term survival of AVF to inform
strategic decision-making in access planning to achieve
maximum beneﬁt in terms of functional dialysis use.METHODS
Retrospective analysis of two prospectively maintained
databases of vascular access operations and dialysis ses-
sions in a single Hospital Trust. The study period was from
December 1, 2002, to December 31, 2011 with follow-up
until December 31, 2014. All operations and dates of
operation were corroborated with the Hospital Episodes
Statistics and electronic patient records. Additional infor-
mation was sought from the home dialysis team, the
vascular access coordinators, or the dialysis unit.
We used a strict deﬁnition of functional dialysis use as a
measurement for primary failure (PF) and maturation rates.
A ﬁstula was deﬁned as mature if it was used for dialysis for
six consecutive dialysis sessions with two needles, resulting
in central venous catheter (CVC)-free dialysis. In a small
minority of patients (2.8%) who had not started dialysis, an
AVF was deemed mature if an experienced dialysis nurse
considered that the AVF could be used for dialysis based on
clinical examination. PF is deﬁned as failure to provide
dialysis for six consecutive sessions on two needles. An AVF
was coded as PF if the pre-dialysis team considered that the
AVF had failed in patients who had not started dialysis
during the study period. Our PF deﬁnition includes imme-
diate failure, early dialysis suitability failure, and late dialysis
suitability failure.12,14 We did not use duplex ultrasound
criteria to assess ﬁstula maturation.
Maturation time was deﬁned as the time from the date
of operation to the date of the sixth consecutive dialysis
session with two needles. This is when the CVC is removed,
indicating the start of CVC-free dialysis. Maturation time
was only estimated for patients already on dialysis on a CVC
at the time of the AVF operation, as there are clinical and
ﬁnancial incentives to use the AVF as soon as it is mature in
order to remove the CVC.15 The time until the sixth
needling date reﬂects the true maturation time of the AVF
in only these patients, as it avoids confounding by indica-
tion, that is the time to needling in pre-dialysis patients,
related to decline in renal function.
Cumulative patency was deﬁned according to the North
American Vascular Access Consortium criteria, as ﬁstula
survival from the operation date to the last needling date
before the AVF was abandoned for a new form of access,
irrespective of any interventions.14 PF was included in the
estimates of cumulative patency. The cumulative patency
rates of the AVF with PF were set at 1 day, as accurate dates
of failure were not available for those AVF. A revision, more
proximal in the forearm, was not coded as a new AVF if the
patient continued to dialyse on the AVF within three dialysis
sessions. An elbow AVF above a forearm AVF was always
coded as a new AVF and the forearm AVF as failed. Patientswere censored at the last needling date if they died, moved
away, underwent renal transplantation, or switched to
peritoneal dialysis. To estimate total functional dialysis use
the total time at risk of failure for all AVF was calculated,
expressed as dialysis-person-years (py). This is the product
of number of AVF operations in the group, and the total
time each AVF was used for dialysis, per 100 AVF opera-
tions. Diabetes was coded as recorded on the dialysis
database and the electronic patient records. The cause of
chronic kidney disease (CKD) was coded as diabetic,
vascular CKD (hypertensive or renovascular disease), auto-
immune CKD (glomerulonephritis, vasculitis, anti-
glomerular basement membrane disease, etc.), post-renal
CKD (obstructive urological causes), polycystic kidney dis-
ease, and other or unknown as per nephrology records.Access planning protocol
The most distal site was chosen to create an AVF in order to
preserve the maximum number of future access sites.1,2
The “more distal rule” takes precedence in the unit over
the “non-dominant arm rule”. A BCAVF is made if all fore-
arm sites in both arms are exhausted. Since August 31,
2004, ultrasound criteria have been used as part of a trial16
and from October 1, 2007, ultrasound criteria were adopted
routinely. An RCAVF was chosen if the radial artery was
2 mm or more and the forearm cephalic vein was 2 mm or
more and in continuity to the elbow. A BCAVF was chosen if
the brachial artery was 3 mm or more and an elbow vein
was 3 mm or more. A BBAVF was made if the brachial artery
was 3 mm or more and the basilic vein at the elbow was
3 mm or more.16 The same criteria to select site of AVF was
used for all age groups.Statistical analysis
Comparisons of categorical data were made using chi-
square tests. Continuous variables were analysed using
the Student t-test or one-way ANOVA. Cumulative patency
data were compared with life table methods and log-rank
tests of survival function. Multivariate analysis of PF was
done using logistic regression methods and multivariable
survival analysis with Cox proportional hazard models.
Automated stepwise regression was not used; a model that
included age, sex, and type of AVF was used and variables
added according to the univariate analysis. Variables were
kept in the model if p < .05 on the likelihood ratio test. All
statistical calculations were done with STATA 12 for
Macintosh (STATA Corporation, TX, USA).
This study was a follow-up study using routinely collected
data. No experimentation was performed and no patients
were contacted outside their routine clinical care.
RESULTS
Study population
Altogether 1249 AVF operations were performed over the
study period: 905 (72.5%) AVF were needled for dialysis and
344 (27.5%) AVF were not used. Of these 344 AVF that were
Table 1. Main characteristics by type of AVF.
Variable RCAVF BCAVF BBAVF p
Male 430 (62%) 196 (51%) 72 (54%) 0.001
Diabetes 271 (39%) 160 (42%) 46 (34%) 0.31
Vascular CKD 94 (14%) 47 (12%) 12 (9%) 0.32
Auto-immune CKD 66 (10%) 49 (13%) 22 (16%) 0.04
Polycystic CKD 33 (5%) 11 (3%) 6 (4%) 0.31
Post-renal CKD 45 (7%) 22 (6%) 6 (4%) 0.63
Pre-dialysis 378 (55%) 158 (41%) 12 (9%) <0.001
Previous AVF 39 (6%) 89 (23%) 59 (44%) <0.001
Access surgeon 609 (88%) 326 (85%) 113 (85%) 0.20
AVF ¼ arteriovenous ﬁstula; BB ¼ brachiobasilic;
BC ¼ brachiocephalic; CKD ¼ chronic kidney disease;
RC ¼ radiocephalic.
Previous AVF indicates previous AVF in the same arm. Access
surgeon indicates three surgeons with a signiﬁcant elective
vascular access workload (Table 7, electronic supplementary
material).
Table 2. Study population and univariate analysis of primary
failure.
Variable Mature
(n ¼ 926)
PF
(n ¼ 280)
Total p
Male 557 (80%) 141 (20%) 698 (58%) 0.004
Female 369 (73%) 139 (27%) 508 (42%)
Diabetic 360 (76%) 117 (24%) 477 (40%) 0.39
Non-diabetic 566 (78%) 163 (22%) 729 (60%)
Age 65 375 (77%) 110 (23%) 485 (40%)
Age 65e80 410 (77%) 124 (23%) 534 (44%) 0.87
Age >80 141 (75%) 46 (25%) 187 (16%)
Vascular CKD 105 (69%) 48 (31%) 153 (13%) 0.011
Non-vascular CKD 821 (78%) 232 (22%) 1053 (87%)
Polycystic CKD 41 (82%) 9 (18%) 50 (4%) 0.39
Non-polycystic CKD 885 (77%) 271 (23%) 1156 (96%)
Autoimmune CKD 105 (77%) 32 (23%) 137 (11%) 0.93
Non-autoimmune 823 (77%) 246 (23%) 1069 (89%)
Post-renal CKD 53 (73%) 20 (27%) 73 (6%) 0.37
Non-post-renal CKD 873 (77%) 260 (23%) 1133 (94%) e
RCAVF 511 (74%) 178 (26%) 689 (57%) e
BCAVF 316 (83%) 67 (17%) 383 (32%) 0.006
BBAVF 99 (74%) 35 (26%) 134 (11%) e
On dialysis at
AVF op
510 (78%) 148 (23%) 658 (55%) 0.61
Pre dialysis at
AVF op
416 (76%) 132 (24%) 548 (45%)
Previous AVF
same side
143 (76%) 44 (24%) 187 (16%) 0.91
No AVF same side 783 (77%) 236 (23%) 1019 (84%)
AVF ¼ arteriovenous ﬁstula; BB ¼ brachiobasilic;
BC ¼ brachiocephalic; CKD ¼ chronic kidney disease;
PF ¼ primary failure; RC ¼ radiocephalic.
The numbers and percentages in the total column represent the
numbers and percentages of the operations in subjects with the
variable in the study population. The numbers and percentages
in the used (for dialysis) and PF column represent the numbers
of ﬁstulae (AVF) with the variable in the used and PF groups.
The numbers and percentages in the total column represent the
number and percentages with that variable in the study
population.
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for dialysis but had not been used. A further 37 (3.0%) AVF
had an unknown outcome, as no record of AVF failure and no
record of dialysis use was made; 26 (2.1%) patients had died;
one had a pre-emptive kidney transplant and 10 (0.8%) were
lost to follow-up. These 37 AVF with unknown outcomes
were excluded from analysis. Six (0.5%) non-standard AVF (1
ulnocephalic AVF, 2 ulnobasilic AVF, and 3 radiobasilic AVF)
were also excluded (Fig. 4 and Table 7, electronic supple-
mentary material). Most (96%) brachiobasilic transpositions
(BBAVF) were one-stage procedures, and 92% of BBAVF were
done under general anaesthesia. Local anaesthesia was used
for 91% for radiocephalic AVF (RCAVF) and 93% of brachio-
cephalic AVF (BCAVF). Eighty-nine arteriovenous grafts were
implanted in the study period.
Altogether, 1206 AVF were used for analysis; 689 (57%)
RCAVF at the wrist or in the forearm; 383 (32%) BCAVF at
the elbow and 134 (11%) BBAVF. The median age of the
patients was 70 years (range 18e92 years), 58% were male,
and 40% were diabetic. The main characteristics by type
AVF is shown in Table 1.Primary failure
PF occurred in 280 (23%) of the 1206 AVF; 926 (77%) AVF
had not failed; 895 AVF of these 926 AVF (97%) were used
for six consecutive dialysis sessions and 31 AVF (3%) were
mature, but dialysis had not started after a mean post-
operative follow-up of 4.2 years (range 2.5e10 years). A
total of 905 (75%) of AVF were used for dialysis, but 10 AVF
failed to achieve functional dialysis use so were coded as
PF, leading to a functional dialysis use in 895 of 1206 AVF
(74%). CVC-free dialysis use occurred in 885 of 1206 AVF
(73%). CVC-free dialysis use of the AVF was 71% in RCAVF,
78% in BCAVF, and 72% in BBAVF (p ¼ .057). Age at
operation was not associated with PF: mean age (SD) for
AVF with PF was 65.8  15.4 years, and mean age for AVF
that were used for dialysis was 66.3  15.0 years (p ¼ .68).
PF was signiﬁcantly lower in BCAVF and in men. PF was
higher in patients with vascular CKD (Table 2).Multivariate analysis showed that female gender, non-
BCAVF, and vascular CKD were independent predictors of
PF. Age, diabetes, pre-dialysis state at time of ﬁstula crea-
tion, previous AVF on the same side and operating surgeon
were not associated with PF (Table 5, electronic supple-
mentary material).Maturation time
Some 658 (55%) patients were on dialysis on a CVC at the
time of AVF creation. These cases were used to calculate
the maturation time, as the time to needling in these pa-
tients reﬂects the true AVF maturation and avoids con-
founding by indication, related to decline in renal function
in pre-dialysis patients. Maturation time was estimated till
the date of functional dialysis use on the ﬁstula, reﬂecting
the start of CVC-free dialysis. Maturation time was available
for 449 of the 658 patients who were on dialysis when the
AVF was created, 151 of the missing 159 cases were AVF
with PF. We did not have an accurate maturation date,
Table 3. Percentiles of maturation time by type of AVF.
Percentile RCAVF
(n ¼ 220)
BCAVF
(n ¼ 152)
BBAVF
(n ¼ 77)
All
(n ¼ 449)
P10 5.9 5 7 5.9
P25 7.1 7.2 9.1 7.4
Median 10.3 9.4 13.4 10.3
P75 16.6 13.7 17.9 16.3
P90 33.9 22.3 33 30
AVF ¼ arteriovenous ﬁstula; BB ¼ brachiobasilic;
BC ¼ brachiocephalic; CKD ¼ chronic kidney disease;
PF ¼ primary failure; RC ¼ radiocephalic.
Maturation time is deﬁned as time in weeks from operation till
date of the sixth consecutive cannulation with two needles on
the ﬁstula, and only calculated for patients who were on dialysis
via a central venous catheter at time of AVF creation.
Figure 2. Cumulative patency by pre-dialysis state. KaplaneMeier
arteriovenous ﬁstula (AVF) cumulative patency, including primary
failures (PFs), curves from operation date to last needling date by
dialysis state at time of AVF creation. Cumulative patency of AVF
with PF was set at 1 day.
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with two needles for eight cases. The median maturation
time was 10.3 weeks (IQR: 7.4e16.3 weeks). Percentiles of
maturation times by type AVF are shown in Table 3.
Maturation times were statistically signiﬁcantly different for
different AVF; the BCAVF had shorter maturation times and
BBAVF longer maturation times than RCAVF (Fig. 5, elec-
tronic supplementary material) (KruskaleWallis chi
square ¼ 13.4, 2 d.f., p ¼ .013). Women (median: 11.2
weeks; IQR 8.4e17.1 weeks) had longer maturation times
than men (median 9.6 weeks; IQR 7.1e15 weeks; p ¼ .02).
Age, diabetes (p ¼ .33) and vascular CKD (p ¼ .91) had no
signiﬁcant effect on maturation times. Only female gender
was independently associated with maturation time in a
regression model adjusted for type of AVF, age, sex, dia-
betes, vascular CKD, and previous AVF on the same side.AVF survival
Cumulative patency, including PF, of RCAVF was signiﬁcantly
better than BCAVF and BBAVF (Fig. 1, log-rank test: chi
square ¼ 23.7, p < .003). The pre-dialysis state at the time
of AVF creation was associated with signiﬁcantly better AVFFigure 1. Cumulative patency by type of arteriovenous ﬁstula
(AVF). KaplaneMeier AVF cumulative patency curves, including
primary failures (PFs), from operation date to last needling date by
type AVF. Cumulative patency of AVF with PF was set at 1 day.cumulative patency (Fig. 2, log-rank test: chi square ¼ 24.7,
p < .0001). Cumulative patency was worse in women if PF
was included in the survival estimates (Fig. 3, log-rank test:
p ¼ .0005), but was not statistically signiﬁcantly different if
PF was excluded (log-rank test: chi square ¼ 2.6, p ¼ .11).
Diabetes was associated with decreased AVF survival (log-
rank test: chi square ¼ 6.4, p ¼ .017). Cumulative patency
was similar in patients with vascular CKD (log-rank test: chi
square ¼ 0.02, p ¼ .88), or across the age categories (log-
rank test: chi square ¼ 5.6, p ¼ .13). Multivariate analysis
using a Cox proportional hazard model (Table 6, electronic
supplementary material) showed that female gender, dia-
betes, and being on dialysis at AVF creation were inde-
pendent predictors of decreased AVF survival. The
proportionality assumption, tested with Schoenfeld re-
siduals was valid (p ¼ .11).Figure 3. Cumulative patency by gender. KaplaneMeier arterio-
venous ﬁstula (AVF) cumulative patency, including primary failures
(PFs), from operation date to last needling date by gender.
Cumulative patency of AVF with PF was set at 1 day.
Table 4. Functional dialysis time.
Group Type
AVF
N Total
dialysis-py
Dialysis-py/100
operations
All RCAVF 689 1588 230.5 (104%)
All BCAVF 383 853 222.7 (100%)
80þ RCAVF 132 257 194.7 (115%)
80þ BCAVF 58 98 169 (100%)
Pre-dialysis RCAVF 548 1315 240.0 (113%)
On dialysis BCAVF 658 1400 212.8 (100%)
AVF ¼ arteriovenous ﬁstula; BB ¼ brachiobasilic;
BC ¼ brachiocephalic; py ¼ person-years; RC ¼ radiocephalic.
Comparison of functional dialysis time, calculated as the dialysis-py
in years, which is the product of total number of AVF operations
and the time each AVF was used for dialysis, per 100 AVF
operations, for RCAVF and BCAVF, by age group and dialysis
state at operation. AVF with primary failure are included by
setting the cumulative patency at 1 day for AVF with primary
failure.
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RCAVF had the best cumulative patency whereas BCAVF
had the lowest PF risk and highest proportion of CVC-free
use. The population beneﬁt of RCAVF with BCAVF was
compared by estimating total functional dialysis use,
calculated as the product of total number of AVF operations
and the time each AVF was used for dialysis, per 100 AVF
operations. PF was included in the analysis by setting AVF
cumulative patency at 1 day for all AVF with PF. All RCAVF
operations resulted in a beneﬁt of 7.8 dialysis-py or 3.5%
(Table 4). The RCAVF operations, in patients over 80,
resulted in a population beneﬁt of 25.7 dialysis-py, or 15%.
An RCAVF results in greater CVC-free dialysis use if the AVF
is used for longer than 1.5 years after its creation (Fig. 1).
The median postoperative survival of patients over 80 was 3
years; 75% lived more than 15 months, and only 10% died
within 6 months of AVF operation. AVF operations in pre-
dialysis patients resulted in a population beneﬁt of 27.2
dialysis-py or 13%.
DISCUSSION
This long-term study of all AVF operations in a single
vascular unit, over 9 years, with a follow-up of 13 years,
showed that BCAVFs had the lowest PF and the highest
proportion of initial CVC-free dialysis use, but RCAVFs had
the longest CVC-free dialysis use despite a higher PF rate.
The PF rate of AVF has improved in recent years.12 A
recent meta-analysis shows a PF of 23%, consistent with
this study.12 Others have also found that RCAVF and women
have higher PF.12,13,17 The reasons for higher PF in women
are not clearly understood and are not explained by dif-
ferences in vessel diameters.18 The current results upper
arm AVF are similar to the literature.19,20
AVF created before patients started dialysis had signiﬁ-
cantly better survival. The pre-dialysis state at AVF opera-
tion resulted in 13% more functional dialysis use. This is
likely to be related to prior CVC use.21 It cannot be ascer-
tained whether the AVF was ipsilateral or contralateral to
the CVC. However, most CVC are inserted as right-sidedinternal jugular lines. Left sided AVF had lower PF (19%)
in patients on dialysis than right-sided AVF (28%, p ¼ .011).
There is also evidence that more severe uraemia is associ-
ated with vascular endothelial changes that may impair
ﬁstula survival.22
More importantly, the pre-dialysis state at the time of
AVF creation is modiﬁable by better pre-dialysis organi-
zation and timely access planning. Accurate estimation of
maturation time is vital for planning of AVF creation.
Maturation times were statistically different for different
AVF but the actual differences were fairly small and may
not be clinically relevant. The median maturation time was
1 week shorter for BCAVF than RCAVF while the median
maturation time of a BBAVF was 3 weeks longer. The
longer maturation time of a BBAVF is not a reﬂection of
multiple operations, as 96% were one-stage operations. It
was shown that it takes approximately 10 weeks to have a
50% probability that an AVF is mature enough to be suc-
cessfully used for CVC-free dialysis, and 16 weeks to have
a 75% probability of CVC-free dialysis use. Therefore, an
AVF should be created 3e4 months before the anticipated
start of dialysis to increase the probability of long-term
AVF survival. AVF survival was better for RCAVF than up-
per arm AVF. This could be a reﬂection of the easier
needling of RCAVF or of the venous anatomy, as upper-
arm AVF have one venous outﬂow channel whereas
RCAVF have multiple outﬂow channels.23 Other reasons
for late failure were rare; no RCAVF was ligated; three
BCAVF and four BBAVF were ligated for arm swelling or
infection. Ten procedures for steal syndrome were done on
upper arm AVF.
The strength of our study is that this is a large, unselected
cohort of all AVF created in a single vascular unit with long
and comprehensive follow-up. Only 3% of patients were
censored because of loss to follow-up. There was therefore
little selection or observation bias. Our unit consists of
seven vascular surgeons and four trainees. Three surgeons
performed most vascular access operations during the study
period (Table 7, electronic supplementary material). The
type of surgeon was not associated with outcome. This is
consistent with a previous publication that trainees and
consultants had similar outcomes provided there were
standardized case selection, decision criteria, and operating
procedures.24
The limitations of this study are, ﬁrstly, there are no ac-
curate data on reasons for AVF failure or accurate data on
the number of interventions needed to achieve AVF
maturation. PF due to early thrombosis cannot be distin-
guished from failure to mature. From a previous random-
ized trial, whose patients were included in this study, it is
known that only 16% of the PF were caused by early
thrombosis.16 It is presumed that the majority of PF are due
to failure to mature, which is in keeping with a large
Scottish study.25 There are no accurate data on the number
of revisions needed to ensure maturation. Radiological in-
terventions to improve maturation are not performed in the
unit. Postoperative surveillance by clinical examination,
which is 95% accurate, is used.26 Eighty-three surgical
Strategies for Planning of Vascular Access 139interventions were performed on the AVF in this study: only
27 (30%) were before the start of dialysis on that AVF, of
which 23 were successful. The low number of pre-dialysis
interventions on non-maturing AVF with high success rate
suggests that there is room for improvement. The lower PF
rate of BCAVF could be a reﬂection of vessel sizes but at
present there are no data to conﬁrm this. The major limi-
tation of this study is that it is not randomized. Therefore,
the fact that a patient requires an elbow AVF rather than a
forearm AVF implies poorer vessels, which could affect
long-term patency.1,2,16
CONCLUSION
RCAVF have higher PF, but better survival than upper arm
AVF, and result in more functional dialysis use. RCAVF result
in greater dialysis use if an AVF is used for more than 1.5
years. AVF created pre-dialysis have better survival. Vascular
access planning should allow for a maturation time of 10
weeks, for a 50% probability, and 16 weeks for a 75%
probability, that an AVF can be used. This study suggests
that the best strategy in access planning is to create an
RCAVF, irrespective of age, 4 months before the anticipated
dialysis start.
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